These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 18398945

  • 1. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis.
    Zhao J, Zhao Y, He J, Jia R, Li Z.
    J Rheumatol; 2008 Jun; 35(6):969-74. PubMed ID: 18398945
    [Abstract] [Full Text] [Related]

  • 2. [Significance of citrullinated collagen type II and its antibodies in rheumatoid arthritis].
    Tian X, Bi LQ, Li ZG.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 05; 86(33):2334-8. PubMed ID: 17156630
    [Abstract] [Full Text] [Related]

  • 3. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
    Liu X, Jia R, Zhao J, Li Z.
    J Rheumatol; 2009 Jun 05; 36(6):1136-42. PubMed ID: 19447936
    [Abstract] [Full Text] [Related]

  • 4. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z, Palafox-Sánchez CA, Parra-Rojas I, Martínez-Bonilla GE, del Toro-Arreola S, Ramírez-Dueñas MG, Ocampo-Bermudes G, Muñoz-Valle JF.
    Clin Exp Immunol; 2015 Nov 05; 182(2):119-31. PubMed ID: 26149185
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: relation with clinical features, cytokines and HLA-DRB1].
    Correa PA, Tobón GJ, Citera G, Cadena J, Schneeberger E, Camargo JF, Maldonado-Cocco JA, Anaya JM.
    Biomedica; 2004 Jun 05; 24(2):140-52. PubMed ID: 15495594
    [Abstract] [Full Text] [Related]

  • 9. Prevalence and significance of antibodies to citrullinated human papilloma virus-47 E2345-362 in rheumatoid arthritis.
    Shi J, Sun X, Zhao Y, Zhao J, Li Z.
    J Autoimmun; 2008 Sep 05; 31(2):131-5. PubMed ID: 18511237
    [Abstract] [Full Text] [Related]

  • 10. The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus.
    Qing YF, Zhang QB, Zhou JG, Yuan GH, Wei J, Xing Y, Liu JP, Jiang L, Chen JP.
    Lupus; 2009 Jul 05; 18(8):713-7. PubMed ID: 19502267
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR.
    J Rheumatol; 2008 Jun 05; 35(6):1002-8. PubMed ID: 18398946
    [Abstract] [Full Text] [Related]

  • 14. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity.
    Halvorsen EH, Pollmann S, Gilboe IM, van der Heijde D, Landewé R, Ødegård S, Kvien TK, Molberg Ø.
    Ann Rheum Dis; 2008 Mar 05; 67(3):414-7. PubMed ID: 18006540
    [Abstract] [Full Text] [Related]

  • 15. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L, Szekanecz Z, Szabó Z, Fekete A, Zeher M, Horváth IF, Dankó K, Kapitány A, Végvári A, Sipka S, Szegedi G, Lakos G.
    J Rheumatol; 2007 Aug 05; 34(8):1658-63. PubMed ID: 17611988
    [Abstract] [Full Text] [Related]

  • 16. Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study.
    Amezcua-Guerra LM, Springall R, Marquez-Velasco R, Gómez-García L, Vargas A, Bojalil R.
    Arthritis Res Ther; 2006 Aug 05; 8(5):R144. PubMed ID: 16934155
    [Abstract] [Full Text] [Related]

  • 17. [T cell proliferative response and antibody formation to citrullinated collagen type II in patients with rheumatoid arthritis].
    Tian X, Zhao Y, Li ZG.
    Zhonghua Yi Xue Za Zhi; 2009 Mar 17; 89(10):673-6. PubMed ID: 19595060
    [Abstract] [Full Text] [Related]

  • 18. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
    Lim MK, Sheen DH, Lee YJ, Mun YR, Park M, Shim SC.
    J Rheumatol; 2009 Apr 17; 36(4):712-6. PubMed ID: 19286846
    [Abstract] [Full Text] [Related]

  • 19. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP, van der Woude D, Ioan-Facsinay A, Levarht EW, Stoeken-Rijsbergen G, Huizinga TW, Toes RE, van der Helm-van Mil AH.
    Arthritis Rheum; 2009 Aug 17; 60(8):2232-41. PubMed ID: 19644872
    [Abstract] [Full Text] [Related]

  • 20. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M, Vidali M, De Andrea M, Azzimonti B, Airò P, D'Ambrosio R, Riboldi P, Meroni PL, Albano E, Shoenfeld Y, Gariglio M, Landolfo S.
    Arthritis Rheum; 2006 Dec 17; 54(12):3939-44. PubMed ID: 17133607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.